These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 32661157)

  • 1. Adjuvanted H5N1 influenza vaccine enhances both cross-reactive memory B cell and strain-specific naive B cell responses in humans.
    Ellebedy AH; Nachbagauer R; Jackson KJL; Dai YN; Han J; Alsoussi WB; Davis CW; Stadlbauer D; Rouphael N; Chromikova V; McCausland M; Chang CY; Cortese M; Bower M; Chennareddy C; Schmitz AJ; Zarnitsyna VI; Lai L; Rajabhathor A; Kazemian C; Antia R; Mulligan MJ; Ward AB; Fremont DH; Boyd SD; Pulendran B; Krammer F; Ahmed R
    Proc Natl Acad Sci U S A; 2020 Jul; 117(30):17957-17964. PubMed ID: 32661157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of broadly cross-reactive antibody responses to the influenza HA stem region following H5N1 vaccination in humans.
    Ellebedy AH; Krammer F; Li GM; Miller MS; Chiu C; Wrammert J; Chang CY; Davis CW; McCausland M; Elbein R; Edupuganti S; Spearman P; Andrews SF; Wilson PC; García-Sastre A; Mulligan MJ; Mehta AK; Palese P; Ahmed R
    Proc Natl Acad Sci U S A; 2014 Sep; 111(36):13133-8. PubMed ID: 25157133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of immune responses to H5N1 inactivated influenza vaccine among individuals previously primed with H5N2 live attenuated influenza vaccine.
    Rudenko L; Naykhin A; Donina S; Korenkov D; Petukhova G; Isakova-Sivak I; Losev I; Stukova M; Erofeeva M; Nikiforova A; Power M; Flores J
    Hum Vaccin Immunother; 2015; 11(12):2839-48. PubMed ID: 26697973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study.
    Leroux-Roels I; Roman F; Forgus S; Maes C; De Boever F; Dramé M; Gillard P; van der Most R; Van Mechelen M; Hanon E; Leroux-Roels G
    Vaccine; 2010 Jan; 28(3):849-57. PubMed ID: 19835828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. H5N1 influenza vaccine formulated with AS03 A induces strong cross-reactive and polyfunctional CD4 T-cell responses.
    Moris P; van der Most R; Leroux-Roels I; Clement F; Dramé M; Hanon E; Leroux-Roels GG; Van Mechelen M
    J Clin Immunol; 2011 Jun; 31(3):443-54. PubMed ID: 21174144
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cell-Based Systems Biology Analysis of Human AS03-Adjuvanted H5N1 Avian Influenza Vaccine Responses: A Phase I Randomized Controlled Trial.
    Howard LM; Hoek KL; Goll JB; Samir P; Galassie A; Allos TM; Niu X; Gordy LE; Creech CB; Prasad N; Jensen TL; Hill H; Levy SE; Joyce S; Link AJ; Edwards KM
    PLoS One; 2017; 12(1):e0167488. PubMed ID: 28099485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity and safety of an AS03-adjuvanted H5N1 pandemic influenza vaccine in Korean adults: a phase IV, randomized, open-label, controlled study.
    Izurieta P; Kim WJ; Wie SH; Lee J; Lee JS; Dramé M; Vaughn DW; Schuind A
    Vaccine; 2015 Jun; 33(24):2800-7. PubMed ID: 25910919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and immunogenicity of a vero cell culture-derived whole-virus H5N1 influenza vaccine in chronically ill and immunocompromised patients.
    van der Velden MV; Geisberger A; Dvorak T; Portsmouth D; Fritz R; Crowe BA; Herr W; Distler E; Wagner EM; Zeitlinger M; Sauermann R; Stephan C; Ehrlich HJ; Barrett PN; Aichinger G
    Clin Vaccine Immunol; 2014 Jun; 21(6):867-76. PubMed ID: 24739978
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A live attenuated H5N2 prime- inactivated H5N1 boost vaccination induces influenza virus hemagglutinin stalk specific antibody responses.
    Kongchanagul A; Samnuan K; Wirachwong P; Surichan S; Puthavathana P; Pitisuttithum P; Boonnak K
    Vaccine; 2020 Jan; 38(4):852-858. PubMed ID: 31708176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity and Safety of an EB66 Cell-Culture-Derived Influenza A/Indonesia/5/2005(H5N1) AS03-Adjuvanted Vaccine: A Phase 1 Randomized Trial.
    Schuind A; Segall N; Drame M; Innis BL
    J Infect Dis; 2015 Aug; 212(4):531-41. PubMed ID: 25722291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-cross-reactive epitopes dominate the humoral immune response to COVID-19 vaccination - kinetics of plasma antibodies, plasmablasts and memory B cells.
    Wietschel KA; Fechtner K; Antileo E; Abdurrahman G; Drechsler CA; Makuvise MK; Rose R; Voß M; Krumbholz A; Michalik S; Weiss S; Ulm L; Franikowski P; Fickenscher H; Bröker BM; Raafat D; Holtfreter S
    Front Immunol; 2024; 15():1382911. PubMed ID: 38807606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I and II randomised trials of the safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in healthy adults.
    Nolan TM; Richmond PC; Skeljo MV; Pearce G; Hartel G; Formica NT; Höschler K; Bennet J; Ryan D; Papanaoum K; Basser RL; Zambon MC
    Vaccine; 2008 Aug; 26(33):4160-7. PubMed ID: 18599164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prepandemic influenza vaccine H5N1 (split virion, inactivated, adjuvanted) [Prepandrix]: a review of its use as an active immunization against influenza A subtype H5N1 virus.
    Carter NJ; Plosker GL
    BioDrugs; 2008; 22(5):279-92. PubMed ID: 18778110
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A clinical phase I study of an EB66 cell-derived H5N1 pandemic vaccine adjuvanted with AS03.
    Naruse T; Fukuda T; Tanabe T; Ichikawa M; Oda Y; Tochihara S; Kimachi K; Kino Y; Ueda K
    Vaccine; 2015 Nov; 33(45):6078-84. PubMed ID: 26409141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cell culture (Vero cell) derived whole-virus non-adjuvanted H5N1 influenza vaccine induces long-lasting cross-reactive memory immune response: homologous or heterologous booster response following two dose or single dose priming.
    van der Velden MV; Aichinger G; Pöllabauer EM; Löw-Baselli A; Fritsch S; Benamara K; Kistner O; Müller M; Zeitlinger M; Kollaritsch H; Vesikari T; Ehrlich HJ; Barrett PN
    Vaccine; 2012 Sep; 30(43):6127-35. PubMed ID: 22884662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heterologous prime-boost vaccination with MF59-adjuvanted H5 vaccines promotes antibody affinity maturation towards the hemagglutinin HA1 domain and broad H5N1 cross-clade neutralization.
    Khurana S; Coyle EM; Dimitrova M; Castellino F; Nicholson K; Del Giudice G; Golding H
    PLoS One; 2014; 9(4):e95496. PubMed ID: 24755693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Flow cytometry reveals that H5N1 vaccination elicits cross-reactive stem-directed antibodies from multiple Ig heavy-chain lineages.
    Whittle JR; Wheatley AK; Wu L; Lingwood D; Kanekiyo M; Ma SS; Narpala SR; Yassine HM; Frank GM; Yewdell JW; Ledgerwood JE; Wei CJ; McDermott AB; Graham BS; Koup RA; Nabel GJ
    J Virol; 2014 Apr; 88(8):4047-57. PubMed ID: 24501410
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined administration of MF59-adjuvanted A/H5N1 prepandemic and seasonal influenza vaccines: long-term antibody persistence and robust booster responses 1 year after a one-dose priming schedule.
    Lopez P; Caicedo Y; Sierra A; Tilman S; Clemens R; Banzhoff A
    Clin Vaccine Immunol; 2013 May; 20(5):753-8. PubMed ID: 23536690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells.
    Throsby M; van den Brink E; Jongeneelen M; Poon LL; Alard P; Cornelissen L; Bakker A; Cox F; van Deventer E; Guan Y; Cinatl J; ter Meulen J; Lasters I; Carsetti R; Peiris M; de Kruif J; Goudsmit J
    PLoS One; 2008; 3(12):e3942. PubMed ID: 19079604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the cellular immune responses induced by a non-adjuvanted inactivated whole virus A/H5N1/VN/1203 pandemic influenza vaccine in humans.
    Crowe BA; Brühl P; Gerencer M; Schwendinger MG; Pilz A; Kistner O; Koelling-Schlebusch K; Aichinger G; Singer J; Zeitlinger M; Müller M; Ehrlich H; Barrett PN
    Vaccine; 2010 Dec; 29(2):166-73. PubMed ID: 21055500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.